Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | F9 | P00740 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAP2 | P11137 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066571 | 0.89 | PDE2A (0.43) | ALPLALPIALPGMLKLPDE2A | |
| SCHEMBL14763165 | 0.87 | ALPL (0.40) | ALPLALPIALPGMLKLPDE2A | |
| SCHEMBL12065625 | 0.87 | MLKL (0.55) | MLKLPDE2AGRIN2BKMOF9 | |
| SCHEMBL14770671 | 0.87 | MLKL (0.43) | ALPLALPIALPGMLKLBRD4 | |
| SCHEMBL12065634 | 0.86 | MLKL (0.40) | MLKLPDE2AGRIN2BKMOF9 | |
| SCHEMBL12065658 | 0.85 | MLKL (0.43) | ALPLALPIALPGMLKLPDE2A | |
| SCHEMBL12065245 | 0.83 | ALPL (0.44) | ALPLALPIALPGMLKLPDE2A | |
| SCHEMBL14762969 | 0.83 | GRIN2B (0.36) | PDE2AGRIN2BKMOBRD4EGLN1 | |
| SCHEMBL14770488 | 0.77 | BRD4 (0.43) | ALPLALPIALPGMLKLBRD4 | |
| SCHEMBL12065613 | 0.77 | ALPL (0.47) | ALPLALPIALPGMLKLPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | claimed |
| EP-2578573-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA Eiyo Ltd. (JP) | 2013-04-10 | — | — | EP | claimed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | claimed |
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| EP-2578573-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA Eiyo Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| WO-2011148956-A1 | FUSED IMIDAZOLE DERIVATIVE | トーアエイヨー株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | ALPL 4272/4885ALPI 3147/4885ALPG 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.